Roivant Sciences: Significant Efficacy in Pulmonary Hypertension Strengthens Pipeline Potential
Reading Time: 3 minutes
Roivant employs a decentralized model for bringing acquired drug candidates to market. Mosliciguat significantly reduced vascular resistance in Phase 2 patients with PH-ILD. The new Phase 3 study targets revenue opportunities in an underserved healthcare market. Decentralized Structure as a Driver of Clinical Innovation Roivant Sciences (ROIV) pursues a business model based on decentralized subsidiaries (so-called Vants). This allows the company to flexibly develop drug candidates that are often licensed in early stages by large pharmaceutical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
